Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus.

about

Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus.Lupus community panel proposals for optimising clinical trials: 2018.

P2860

Q47553423-8F27D784-5A4E-47FD-986D-BC574C5E06A5 Q52320880-70EB8C37-C3E0-4E5D-BA91-559995A93B1C

P2860

Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus.

Item

http://www.wikidata.org/entity/Q50575750

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Safety and pharmacodynamics of ...... systemic lupus erythematosus.

@en

Safety and pharmacodynamics of venetoclax

@nl

type

Item

label

Safety and pharmacodynamics of ...... systemic lupus erythematosus.

@en

Safety and pharmacodynamics of venetoclax

@nl

prefLabel

Safety and pharmacodynamics of ...... systemic lupus erythematosus.

@en

Safety and pharmacodynamics of venetoclax

@nl

P1476

Safety and pharmacodynamics of ...... systemic lupus erythematosus.

@en

P2093

C Curtis

http://www.w3.org/2001/XMLSchema#string

J K Medema

http://www.w3.org/2001/XMLSchema#string

J Stolzenbach

http://www.w3.org/2001/XMLSchema#string

J Zeng

http://www.w3.org/2001/XMLSchema#string

K Black

http://www.w3.org/2001/XMLSchema#string

K M Grebe

http://www.w3.org/2001/XMLSchema#string

M Desai

http://www.w3.org/2001/XMLSchema#string

P Lu

http://www.w3.org/2001/XMLSchema#string

R Fleischmann

http://www.w3.org/2001/XMLSchema#string

S H Clarke

http://www.w3.org/2001/XMLSchema#string

P2860

Pathogenesis of systemic lupus erythematosus

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Predominant autoantibody production by early human B cell precursors

Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.

A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE

The role of apoptosis proteins and complement components in the etiopathogenesis of systemic lupus erythematosus.

CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients.

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

P304

290-302

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0961203317719334

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28691866

http://www.w3.org/2001/XMLSchema#string

Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus.

about

P2860

P2860

Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698